Oncology Institute (TOI) EBIAT (2020 - 2025)
Oncology Institute (TOI) has disclosed EBIAT for 6 consecutive years, with -$16.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 2.43% year-over-year to -$16.5 million, compared with a TTM value of -$66.3 million through Sep 2025, up 5.63%, and an annual FY2024 reading of -$64.7 million, up 22.16% over the prior year.
- EBIAT was -$16.5 million for Q3 2025 at Oncology Institute, up from -$17.0 million in the prior quarter.
- Across five years, EBIAT topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
- Average EBIAT over 5 years is -$11.0 million, with a median of -$15.5 million recorded in 2024.
- Peak annual rise in EBIAT hit 2036.35% in 2022, while the deepest fall reached 696.88% in 2022.
- Year by year, EBIAT stood at -$10.2 million in 2021, then decreased by 8.38% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then grew by 29.71% to -$13.2 million in 2024, then decreased by 25.2% to -$16.5 million in 2025.
- Business Quant data shows EBIAT for TOI at -$16.5 million in Q3 2025, -$17.0 million in Q2 2025, and -$19.6 million in Q1 2025.